214 related articles for article (PubMed ID: 21363914)
1. Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy.
Owen MR; Stamper IJ; Muthana M; Richardson GW; Dobson J; Lewis CE; Byrne HM
Cancer Res; 2011 Apr; 71(8):2826-37. PubMed ID: 21363914
[TBL] [Abstract][Full Text] [Related]
2. Macrophage-based anti-cancer therapy: modelling different modes of tumour targeting.
Webb SD; Owen MR; Byrne HM; Murdoch C; Lewis CE
Bull Math Biol; 2007 Jul; 69(5):1747-76. PubMed ID: 17333419
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11.
Jounaidi Y; Chen CS; Veal GJ; Waxman DJ
Mol Cancer Ther; 2006 Mar; 5(3):541-55. PubMed ID: 16546968
[TBL] [Abstract][Full Text] [Related]
4. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.
Post DE; Devi NS; Li Z; Brat DJ; Kaur B; Nicholson A; Olson JJ; Zhang Z; Van Meir EG
Clin Cancer Res; 2004 Dec; 10(24):8603-12. PubMed ID: 15623644
[TBL] [Abstract][Full Text] [Related]
5. Macrophage migration and gene expression in response to tumor hypoxia.
Murdoch C; Lewis CE
Int J Cancer; 2005 Dec; 117(5):701-8. PubMed ID: 16106399
[TBL] [Abstract][Full Text] [Related]
6. The macrophage - a novel system to deliver gene therapy to pathological hypoxia.
Griffiths L; Binley K; Iqball S; Kan O; Maxwell P; Ratcliffe P; Lewis C; Harris A; Kingsman S; Naylor S
Gene Ther; 2000 Feb; 7(3):255-62. PubMed ID: 10694803
[TBL] [Abstract][Full Text] [Related]
7. Mathematical modelling of the use of macrophages as vehicles for drug delivery to hypoxic tumour sites.
Owen MR; Byrne HM; Lewis CE
J Theor Biol; 2004 Feb; 226(4):377-91. PubMed ID: 14759644
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-inducible lentiviral gene expression in engineered human macrophages.
Chinn HK; Gardell JL; Matsumoto LR; Labadie KP; Mihailovic TN; Lieberman NAP; Davis A; Pillarisetty VG; Crane CA
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728871
[TBL] [Abstract][Full Text] [Related]
9. Genetically modified macrophages expressing hypoxia regulated cytochrome P450 and P450 reductase for the treatment of cancer.
Kan O; Day D; Iqball S; Burke F; Grimshaw MJ; Naylor S; Binley K
Int J Mol Med; 2011 Feb; 27(2):173-80. PubMed ID: 21165551
[TBL] [Abstract][Full Text] [Related]
10. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2000 Jul; 60(14):3761-9. PubMed ID: 10919648
[TBL] [Abstract][Full Text] [Related]
11. A clinical protocol for treatment of canine mammary tumors using encapsulated, cytochrome P450 synthesizing cells activating cyclophosphamide: a phase I/II study.
Winiarczyk S; Gradski Z; Kosztolich B; Gabler C; König G; Renner M; Saller RM; Prosl H; Salmons B; Günzburg WH; Hain J
J Mol Med (Berl); 2002 Sep; 80(9):610-4. PubMed ID: 12226743
[No Abstract] [Full Text] [Related]
12. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
Roy P; Waxman DJ
Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.
Braybrooke JP; Slade A; Deplanque G; Harrop R; Madhusudan S; Forster MD; Gibson R; Makris A; Talbot DC; Steiner J; White L; Kan O; Naylor S; Carroll MW; Kingsman SM; Harris AL
Clin Cancer Res; 2005 Feb; 11(4):1512-20. PubMed ID: 15746054
[TBL] [Abstract][Full Text] [Related]
14. Targeting gene therapy to cancer: a review.
Dachs GU; Dougherty GJ; Stratford IJ; Chaplin DJ
Oncol Res; 1997; 9(6-7):313-25. PubMed ID: 9406237
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy.
Burke B; Giannoudis A; Corke KP; Gill D; Wells M; Ziegler-Heitbrock L; Lewis CE
Am J Pathol; 2003 Oct; 163(4):1233-43. PubMed ID: 14507633
[TBL] [Abstract][Full Text] [Related]
16. In vivo bioluminescence imaging monitoring of hypoxia-inducible factor 1alpha, a promoter that protects cells, in response to chemotherapy.
Viola RJ; Provenzale JM; Li F; Li CY; Yuan H; Tashjian J; Dewhirst MW
AJR Am J Roentgenol; 2008 Dec; 191(6):1779-84. PubMed ID: 19020250
[TBL] [Abstract][Full Text] [Related]
17. Mathematical modelling of a hypoxia-regulated oncolytic virus delivered by tumour-associated macrophages.
Boemo MA; Byrne HM
J Theor Biol; 2019 Jan; 461():102-116. PubMed ID: 30359572
[TBL] [Abstract][Full Text] [Related]
18. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
Emmenegger U; Morton GC; Francia G; Shaked Y; Franco M; Weinerman A; Man S; Kerbel RS
Cancer Res; 2006 Feb; 66(3):1664-74. PubMed ID: 16452226
[TBL] [Abstract][Full Text] [Related]
19. How to overcome (and exploit) tumor hypoxia for targeted gene therapy.
Greco O; Marples B; Joiner MC; Scott SD
J Cell Physiol; 2003 Dec; 197(3):312-25. PubMed ID: 14566961
[TBL] [Abstract][Full Text] [Related]
20. Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy.
Burke B; Tang N; Corke KP; Tazzyman D; Ameri K; Wells M; Lewis CE
J Pathol; 2002 Feb; 196(2):204-12. PubMed ID: 11793372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
